
    
      PRIMARY OBJECTIVES:

      Determine the safety and tolerability of donor T regulatory (Treg) cell infusions in subjects
      with steroid dependent/refractory chronic graft versus host disease.

      SECONDARY OBJECTIVES:

        1. Determine the quantitative blood Treg cell changes following the cell infusions

        2. Determine clinical efficacy of donor Treg cells as failure-free survival (FFS) defined
           by the absence of a new immunosuppressive therapy added, non-relapse mortality, and
           recurrent malignancy at Day 180 after the first Treg infusion

        3. In addition to FFS, the study will measure the change in:

             1. cGVHD symptom burden measured by the Lee cGVHD Symptom Scale by increase in >7
                points

             2. NIH organ-specific cGVHD scale

             3. The reduction in daily corticosteroid requirement of prednisone to <=0.25 mg/kg-day
                at Day 180 after the first Treg infusion
    
  